BioChem wins round to expand way drug used

Article Abstract:

BioChem Pharma Inc. has secured the endorsement of the US Food and Drug Administration's advisory panel on the expansion into chronic-hepatitis-B treatment of the applications of its lamivudine pharmaceutical. BioChem Pharma secured the endorsement with Glaxo Wellcome PLC, its partner firm for marketing initiatives. An approval from the US Food and Drug Administration on the expanded use of lamivudine will establish the drug as the US' first approved oral treatment against the hepatitis B ailment.

Comment:

Secures endorsement of US Food & Drug Admin's advisory panel on expanded use of lamivudine for chronic-hepatitis-B treatment

Government regulation (cont), Pharmaceutical Preparation Manufacturing, Hepatic Preparations, Antiviral agents, Hepatitis, Shire BioChem Inc., Article

---

Laser vision surgery staging comeback

Article Abstract:

The new 'custom' technology used in laser vision surgery is reducing fears of complications and costs $4,500 for the promise of better than 20/20 eyesight. Laser eye correction procedures in the United States are expected to increase by up to 12 per cent in 2004 and jump 35 per cent in 2005.

Forecasts, trends, outlooks, Forecasts and trends, Market trend/market analysis, Lasers in surgery, Laser surgery, Lasers in ophthalmology, Ophthalmic lasers

---

Dissident shareholders launch Wex proxy battle

Article Abstract:

Demands of shareholders of Wex Pharmaceuticals Inc. to replace the existing board are discussed.

Pharmaceutical preparations, Pharmaceutical industry, Stockholders, Demonstrations and protests

Similar abstracts:

• Abstracts: Cuts in bank expenses, services cited if Ottawa rejects mergers. A big dream that 'was going nowhere.'
• Abstracts: Relationships of work and practice environment to professional burnout: Testing a causal model. Nursing-sensitive outcomes data collection in acute care and long-term care settings
• Abstracts: Barrick CEO quita for 'personal reasons'. Stock exchange mergers still on menu. Executive decision: stock up on niche market listings
• Abstracts: Kremlin's tax demands may finish off Yukos. Facts discolour BP's green image. A carbon tax? We have all we can handle
• Abstracts: The weakening of the old boys' network. U.S hedge fund walloped on bad gas bet. Petrocan garners analysts' kudos

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.